Which macrolide has been linked to an increase in cardiac deaths among patients with preexisting conditions?

The macrolide associated with an increase in cardiac deaths among patients with preexisting conditions is azithromycin. This connection is particularly relevant for patients who may have conditions that predispose them to cardiac issues, such as existing heart disease or arrhythmias.

Azithromycin can prolong the QT interval, which can lead to potentially fatal arrhythmias, especially in vulnerable populations. This risk has been documented in several studies and health advisories, highlighting the importance of careful consideration when prescribing azithromycin to patients with known cardiac risks. Although other macrolides like clarithromycin and erythromycin may also have some associated risks, it is the specific risk profile of azithromycin that has been more widely discussed in relation to cardiac mortality in patients with preexisting conditions.

In summary, azithromycin’s link to increased cardiac death is due to its potential effects on heart rhythm, emphasizing a cautious approach in its use among those with underlying cardiac issues.